Chinese Healthcare Firms Poised for Earnings Surge From 2026 — Market Talk

Drugmaker Glenmark Pharmaceuticals Ltd on Tuesday (December 16) said its wholly owned subsidiary Glenmark Specialty S.A. (GSSA) has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co, Ltd. for Aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer.

Under the agreement, Glenmark has received exclusive rights to develop and commercialise Aumolertinib across its licensed territories, which include the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and a few selected Caribbean countries covered by the agreement.

As part of the transaction, Hansoh Pharma will receive an upfront payment of low double-digit million USD. The agreement also provides for potential regulatory and commercial milestone payments that may cumulatively exceed $1 billion, along with tiered royalties on net sales in the licensed territories.

"Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets," said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.

Aumolertinib (marketed as Ameile in China and Aumseqa in the United Kingdom and Europe), as a monotherapy, has received marketing authorisation from the UK MHRA and is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

It has also received approval for four indications in China (second-line T790M mutation, first-line NSCLC EGFR mutated, unresectable Stage III post-chemoradiotherapy, and adjuvant Stage II–IIIB NSCLC). Aumolertinib became Hansoh Pharma’s first innovative drug approved in an overseas market and the first China-developed EGFR-TKI to be launched internationally.

Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,962.00, down by ₹23.60, or 1.19%, on the BSE.

BeOne Medicines could deliver sustainable revenue growth through new product launches, UOB Kay Hian analysts Carol Dou and Sunny Chen say in a note. They view the company's new $5.1 billion-$5.3 billion revenue target as highly achievable and expect further improvements in operating efficiency and cash generation by leveraging its global operating platform. The analysts say BeOne's anticancer treatment Brukinsa will likely continue to lift global sales in coming years, supported by its best-in-class profile and expanding market penetration. "BeOne Medicines has entered a new era of development with positive profit and free cash flow from 2025 onwards," they say, citing a more diversified revenue mix and improving margins. UOB Kay Hian has a buy rating on the stock with a HK$252.00 target. Its H-shares last traded at HK$193.10. (jason.chau@wsj.com)

Revenue grew 17% year-over-year to RMB16.7 billion, with net profit up 64.7% and gross margin at 25.1%. Strong growth in direct sales, e-commerce, and digital health services, supported by digital innovation and strategic partnerships, drove performance.

Original document: Alibaba Health Information Technology Ltd. [241] Interim report — Nov. 27 2025

By Adriano Marchese

BeOne Medicines said U.S. regulators have agreed to fast-track the review its new drug to treat adults with mantle cell lymphoma, a form of blood cancer.

The cancer treatment company said Wednesday that the Food and Drug Administration has accepted and granted priority review to a new drug application for sonrotoclax, a new BCL2 inhibitor intended to treat adult patients with relapsed or refractory mantle cell lymphoma.

Mantle cell lymphoma is a rare, fast-growing blood cancer that starts in the lymph nodes.

The decision was based on data from a phase 1/2 study which enrolled 125 adult patients with the specific type of blood cancer who had received prior treatment. The trial results found that sonorotoclax achieved its primary endpoints of overall response rate, and also showed promising results across several secondary efficacy endpoints, it said.

"Sonrotoclax is advancing with remarkable speed, from breakthrough therapy designation to priority review, all within a short window," Global Head of Research and Development at BeOne, Lai Wang, said.

Write to Adriano Marchese at adriano.marchese@wsj.com

Revenue rose 17% year-over-year to RMB16.7 billion, with net profit up 64.7% and margin improving to 7.6%. Direct sales and e-commerce segments drove growth, while investments in AI and digital health continue. Cash position strengthened, with no interim dividend declared.

Original document: Alibaba Health Information Technology Ltd. [241] Earnings Release — Nov. 27 2025

(18:01 GMT) BeOne Medicines Price Target Announced at $400.00/Share by Truist Securities